Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.

Many investors view the healthcare sector as a safe haven when the stock market is turbulent. Here are three no-brainer ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

And then importantly, now kicking off the growth of our franchise in acute pain with the launch of JOURNAVX. So very, very busy start to the year. We've also got four programs in Phase 3 that will ...

Vertex's success since the early 2010s is due to its work in CF. The company famously markets the only approved medicines that target the underlying causes of this condition. Thanks to its monopoly, ...

In January, the U.S. Food and Drug Administration gave the green light to Journavx, a medicine for acute pain. The point here is that Vertex can develop therapies outside of its core therapeutic ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

It recently won two key U.S. Food and Drug Administration (FDA) approvals, one for CF therapy Alyftrek and another for acute pain drug Journavx (suzetregine). Alyftrek is Vertex's most powerful ...